QuantBioRes A/S: Financial statements 2023
CVR: 41407352
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
QuantBioRes A/S (CVR 41407352) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -1,620,568 and a net result of DKK -1,342,114 compared with DKK -3,065,066 the year before. Equity in the 2023 report amounted to DKK -7,353,148.
- Gross Profit
- DKK -1,620,568
- Profit/Loss
- DKK -1,342,114
- Equity
- DKK -7,353,148
- Total Assets
- DKK 1,185,112
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -1.6 mio. | -1.3 mio. | -7.4 mio. | - |
| 2022 | - | -3.8 mio. | -3.1 mio. | -6 mio. | - |
| 2021 | - | -2.9 mio. | -2.3 mio. | -2.9 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
QuantBioRes A/S has published its annual report for 2022. Gross profit came to DKK -3,770,278, and the net result was DKK -3,065,066.
About QuantBioRes A/S
QuantBioRes A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2020. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Ivan Loncarevic. The board consists of Anthony Slingsby, Mark Andrew Madden and Novak Djokovic. The company is owned by Tulua Doo Beograd - Stari Grad, Anthony Charles Slingsby and Anna Eva Charlotta Slingsby. According to the 2025 annual report, the company had an average of 1 employee. In 2025, the company reported a gross profit of DKK -2,736,412 and a net result of DKK -2,396,479 compared with DKK -1,482,065 the year before. Equity in the 2025 report amounted to DKK 444,094.